GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (OSL:CRNA) » Definitions » Total Liabilities

Circio Holding ASA (OSL:CRNA) Total Liabilities : kr50.65 Mil (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Circio Holding ASA Total Liabilities?

Circio Holding ASA's Total Liabilities for the quarter that ended in Jun. 2024 was kr50.65 Mil.

Circio Holding ASA's quarterly Total Liabilities increased from Jun. 2023 (kr121.63 Mil) to Dec. 2023 (kr124.47 Mil) but then declined from Dec. 2023 (kr124.47 Mil) to Jun. 2024 (kr50.65 Mil).

Circio Holding ASA's annual Total Liabilities declined from Dec. 2021 (kr147.54 Mil) to Dec. 2022 (kr97.85 Mil) but then increased from Dec. 2022 (kr97.85 Mil) to Dec. 2023 (kr124.47 Mil).


Circio Holding ASA Total Liabilities Historical Data

The historical data trend for Circio Holding ASA's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Circio Holding ASA Total Liabilities Chart

Circio Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 159.95 148.15 147.54 97.85 124.47

Circio Holding ASA Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 152.93 97.85 121.63 124.47 50.65

Circio Holding ASA Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Circio Holding ASA's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=124.471+(0+0.00099999999999056
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=124.47

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=28.135--96.337
=124.47

Circio Holding ASA's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=7.487--43.164
=50.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Circio Holding ASA Total Liabilities Related Terms

Thank you for viewing the detailed overview of Circio Holding ASA's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Circio Holding ASA Business Description

Traded in Other Exchanges
Address
Saint Olavs plass, Pb. 6887, Oslo, NOR, 0130
Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients. The company's pipeline candidate includes circVec and Mutant KRAS.

Circio Holding ASA Headlines

No Headlines